LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

7.80

-0.26 (-3.23%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	8.06
Open	8.07
Bid	0.00 x 0
Ask	9.60 x 700
Day's Range	7.77 - 8.25
52 Week Range	7.77 - 18.00
Volume	695,575
Avg. Volume	627,014

Market Cap	823.618M
Beta	0.41
PE Ratio (TTM)	N/A
EPS (TTM)	-1.23
Earnings Date	Apr 30, 2018 - May 4, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	22.20

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire23 hours ago
Lexicon Pharmaceuticals to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 3, 2018
Lexicon Pharmaceuticals, Inc. (LXRX), will release its first quarter 2018 financial results on Thursday, May 3, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
Motley Fool6 days ago
3 Top Biotech Stocks to Buy Right Now
There's good reason to consider buying shares in these biotech companies soon.
GlobeNewswire24 days ago
Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018
THE WOODLANDS, Texas, April 03, 2018-- Lexicon Pharmaceuticals, Inc., announced today that it will host its 2018 Research & Development Day on Tuesday, April 10, 2018, from 8:30 a.m. to 11:30 a.m. EDT ...
American City Business Journals25 days ago
Woodlands pharma co. total revenue 'won’t grow a lot' year over year
"We have a big year ahead of us."
GlobeNewswire29 days ago
Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes
THE WOODLANDS, Texas, March 29, 2018-- Lexicon Pharmaceuticals, Inc., today announced that the European Medicines Agency has accepted the Marketing Authorization Application filed by Lexicon’ s collaborator, ...
ACCESSWIRElast month
Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes
Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: ...
Thomson Reuters StreetEventslast month
Edited Transcript of LXRX earnings conference call or presentation 22-Feb-18 1:00pm GMT
Q4 2017 Lexicon Pharmaceuticals Inc Earnings Call
GlobeNewswirelast month
Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes
New Drug Application Submitted to U.S. Marketing Authorization Application Submitted to European Medicines Agency. THE WOODLANDS, Texas, March 26, 2018-- Lexicon Pharmaceuticals, Inc., today announced ...
Markit2 months ago
See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
GuruFocus.com2 months ago
Lexicon Pharmaceuticals Inc (LXRX) Files 10-K for the Fiscal Year Ended on December 31, 2017
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
GlobeNewswire2 months ago
Lexicon Pharmaceuticals Announces Poster Presentation at the 15th Annual ENETS Conference
THE WOODLANDS, Texas, Feb. 28, 2018-- Lexicon Pharmaceuticals, Inc., announced today that data from a poster highlighting XERMELO ® will be presented at the upcoming 15 th Annual European Neuroendocrine ...
GlobeNewswire2 months ago
Lexicon Pharmaceuticals to Present at Upcoming Investor Conferences
THE WOODLANDS, Texas, Feb. 27, 2018-- Lexicon Pharmaceuticals, Inc. today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, ...
Markit2 months ago
See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
Associated Press2 months ago
Lexicon reports 4Q loss
The The Woodlands, Texas-based company said it had a loss of 27 cents per share. Losses, adjusted for pretax gains, came to 31 cents per share. The results exceeded Wall Street expectations. The average ...
GlobeNewswire2 months ago
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides a Business Update
Net Sales Since March 2017 Launch Reach $15.1 Million. Regulatory Filings for Sotagliflozin in Patients with Type 1 Diabetes Expected in First Quarter of 2018. THE WOODLANDS, Texas, Feb. 22, 2018-- Lexicon ...
ACCESSWIRE2 months ago
Lexicon Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 8:00 ...
GlobeNewswire2 months ago
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 22, 2018
THE WOODLANDS, Texas, Feb. 16, 2018-- Lexicon Pharmaceuticals, Inc., will release its fourth quarter and full-year 2017 financial results on Thursday, February 22, 2018 before market opens. Management ...
Motley Fool2 months ago
Here's Why Lexicon Pharmaceuticals Dropped as Much as 13.6% Today
The stock was downgraded by a prominent analyst.
Markit2 months ago
See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
GlobeNewswire3 months ago
Investor Expectations to Drive Momentum within Mettler-Toledo International, Party City Holdco, Old Dominion Freight Line, Sun Hydraulics, Sorrento Therapeutics, and Lexicon Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Feb. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mettler-Toledo ...
Markit3 months ago
See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX
Motley Fool3 months ago
3 Fastest-Growing Diabetes Stocks of 2018 -- According to Wall Street
Analysts think these three diabetes stocks could soar more than 50% this year. But are they right?
Markit3 months ago
See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX